Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of apitegromab in spinal muscular atrophy
NL-OMON59983Phase 3Active, not recruiting
- Sponsor
- Scholar Rock
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of apitegromab, sponsored by Scholar Rock. Started Nov 2023; status: active, not recruiting.
02
Drugs
apitegromab
Beyond the preview
Go deeper on NL-OMON59983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59983.